Skip to main content
. 2022 Mar 8;7(5):e151037. doi: 10.1172/jci.insight.151037

Figure 2. Prophylactic PLG nanoparticle treatment attenuates pulmonary fibrosis in BLM-injected mice.

Figure 2

(A) Schema of experimental setup and treatment regimen. (B) Masson’s trichrome stain (top). Scale bar: 25 μm. Representative images of immunofluorescence staining using Abs to ASMA (green) and MARCO (red) (bottom). Nuclei were identified by DAPI (blue). Scale bar: 200 μm. (C) Lung hydroxyproline (hypro) content. P values determined via 1-way ANOVA followed by the Šidák’s multiple comparison test. *P < 0.05; **P < 0.01. (D) Hubner score. Results are reported as mean ± SD from 5 high-power fields per mouse from at least 5 mice per experimental group. ***P < 0.01. (E) Total number of myofibroblasts (live singlets/CD45–/PDGFR+/CD90+) and α-SMA+ myofibroblasts per whole left lung per mouse (n = 4–5 with 3 independent experiments) measured by flow cytometry. *P < 0.05; **P < 0.01. (F) MicroCT of the lungs. Representative cross-sectional (left- and middle-column panels) and 3D images (right-column panels) (G) Quantitative lung FI (n = 4–5 mice/group with two independent repeats). ****P < 0.0001. (H) Correlative comparison between CT-measured FI and half-lung collagen content by hypro assay. Ctrl, control.